Boehringer Ingelheim, Zealand tout key fibrosis data from mid-stage MASH trial

Boehringer In­gel­heim of­fi­cial­ly un­veiled fi­bro­sis da­ta from a mid-stage tri­al of its Zealand Phar­ma-part­nered drug in MASH on Fri­day, af­ter its liv­er con­gress ab­stract was …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.